Tycel Phillips, MD, on Marginal Zone Lymphoma: Efficacy and Safety of Parsaclisib

January 17, 2022 By The ASCO Post Staff

Tycel Phillips, MD, of the Rogel Cancer Center, University of Michigan, discusses phase II findings from the CITADEL-204 study of parsaclisib, a next-generation inhibitor of phosphatidylinositol 3-kinase. The agent, used as a monotherapy, appeared to benefit patients with relapsed or refractory marginal zone lymphoma who had a rapid and durable clinical response (Abstract 44).

Related Content